title: Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy.
abstract: We report on a 63-year-old man with a history of hepatitis B virus-related hepatocellular carcinoma with a thrombus extending into the inferior vena cava, who received image-guided stereotactic body radiation therapy (SBRT) with helical tomotherapy, followed by sorafenib. A total tumor dose of 48 Gy was delivered by 6 fractions within 2 weeks. The tumor responded dramatically, and the patient tolerated the courses well. Ten days after SBRT, sorafenib (200 mg), at 1.5 tablets twice a day, was prescribed. One week later, grade 2 recall radiation dermatitis subsequently developed in the previous SBRT off-target area. SBRT followed by sorafenib for the treatment of a portal vein thrombosis provided effective results, but the potential risk of enhanced adverse effects between radiation and sorafenib should be considered with caution, especially under a SBRT scheme.
authors: Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan ; Department of Medicine, National Yang-Ming University, Taipei, Taiwan ; Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
authors: Chen-Hsi
authors: CH
authors: Hsieh
authors: Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
authors: Shih-Chiang
authors: SC
authors: Lin
authors: Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan ; Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan ; Oriental Institute of Technology, New Taipei City, Taiwan.
authors: Pei-Wei
authors: PW
authors: Shueng
authors: Division of Radiation Oncology, Department of Radiology, New Taipei City, Taiwan.
authors: Deng-Yu
authors: DY
authors: Kuo
keywords: hepatocellular carcinoma; recall radiation dermatitis